Clinical efficacy of docetaxel combined with carboplatin in patients with metastatic castration-resistant prostate cancer

To observe the early efficacy and toxicity of docetaxel combined with carboplatin in patients with metastatic castration-resistant prostate cancer (mCRPC). From May 2017 to July 2019, fifteen patients with mCRPC treated in Peking University First Hospital were collected. The median age was 70 years...

Full description

Saved in:
Bibliographic Details
Published in:Beijing da xue xue bao. Journal of Peking University. Yi xue ban 2021-08, Vol.53 (4), p.686
Main Authors: Bai, G C, Song, Y, Jin, J, Yu, W, He, Z S
Format: Article
Language:Chinese
Subjects:
Aged
Androgen Antagonists - therapeutic use
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Carboplatin - therapeutic use
Docetaxel - therapeutic use
Humans
Male
Prostate-Specific Antigen
Prostatic Neoplasms, Castration-Resistant - drug therapy
Treatment Outcome
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To observe the early efficacy and toxicity of docetaxel combined with carboplatin in patients with metastatic castration-resistant prostate cancer (mCRPC). From May 2017 to July 2019, fifteen patients with mCRPC treated in Peking University First Hospital were collected. The median age was 70 years (43-77 years), and the pathological types were all adenocarcinoma, which was confirmed as distant metastasis by imaging examination. They were given the chemotherapy of docetaxel combined with carboplatin. The specific method was as follows: each cycle was 28 days. Androgen deprivation therapy was administered routinely throughout the treatment period. Blood routine, liver and kidney function, blood clotting function and prostate-specific antigen (PSA) tests were performed before each cycle. Docetaxel was administered intravenously on the first day of each cycle at a dose of 75 mg/m , and carboplatin was administered intravenously on the second day at the dose calculated by Calvert formula. The main outcome measure
ISSN:1671-167X